Hinrich Gronemeyer
Hinrich Gronemeyer
Research Director (DRE) at the IGBMC Strasbourg-Illkirch, France
Verified email at
Cited by
Cited by
Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
L Galluzzi, I Vitale, SA Aaronson, JM Abrams, D Adam, P Agostinis, ...
Cell Death & Differentiation 25 (3), 486-541, 2018
Two distinct estrogen‐regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B.
P Kastner, A Krust, B Turcotte, U Stropp, L Tora, H Gronemeyer, ...
The EMBO journal 9 (5), 1603-1614, 1990
Principles for modulation of the nuclear receptor superfamily
H Gronemeyer, JÅ Gustafsson, V Laudet
Nature reviews Drug discovery 3 (11), 950-964, 2004
Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
W Bourguet, M Ruff, P Chambon, H Gronemeyer, D Moras
Nature 375 (6530), 377-382, 1995
Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
JP Renaud, N Rochel, M Ruff, V Vivat, P Chambon, H Gronemeyer, ...
Nature 378 (6558), 681-689, 1995
TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors.
JJ Voegel, MJ Heine, C Zechel, P Chambon, H Gronemeyer
The EMBO journal 15 (14), 3667-3675, 1996
A canonical structure for the ligand-binding domain of nuclear receptors
JM Wurtz, W Bourguet, JP Renaud, V Vivat, P Chambon, D Moras, ...
Nature structural biology 3 (1), 87-94, 1996
A unified nomenclature system for the nuclear receptor superfamily
J Auwerx, E Baulieu, M Beato, M Becker-Andre, PH Burbach, G Camerino, ...
Cell 97 (2), 161-163, 1999
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015
L Galluzzi, BS Pedro, I Vitale, SA Aaronson, JM Abrams, D Adam, ...
Cell Death & Differentiation 22 (1), 58-73, 2015
The nuclear receptor ligand-binding domain: structure and function
D Moras, H Gronemeyer
Current opinion in cell biology 10 (3), 384-391, 1998
The promise of retinoids to fight against cancer
L Altucci, H Gronemeyer
Nature Reviews Cancer 1 (3), 181-193, 2001
Senescence-associated reprogramming promotes cancer stemness
M Milanovic, DNY Fan, D Belenki, JHM Däbritz, Z Zhao, Y Yu, JR Dörr, ...
Nature 553 (7686), 96-100, 2018
Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes
L Galluzzi, SA Aaronson, J Abrams, ES Alnemri, DW Andrews, ...
Cell Death & Differentiation 16 (8), 1093-1107, 2009
The N‐terminal part of TIF1, a putative mediator of the ligand‐dependent activation function (AF‐2) of nuclear receptors, is fused to B‐raf in the oncogenic protein T18.
B Le Douarin, C Zechel, JM Garnier, Y Lutz, L Tora, P Pierrat, D Heery, ...
The EMBO journal 14 (9), 2020-2033, 1995
Steroid hormone receptors compete for factors that mediate their enhancer function
ME Meyer, H Gronemeyer, B Turcotte, MT Bocquel, D Tasset, P Chambon
Cell 57 (3), 433-442, 1989
Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications
W Bourguet, P Germain, H Gronemeyer
Trends in pharmacological sciences 21 (10), 381-388, 2000
RAR and RXR modulation in cancer and metabolic disease
L Altucci, MD Leibowitz, KM Ogilvie, AR de Lera, H Gronemeyer
Nature reviews Drug discovery 6 (10), 793-810, 2007
The coactivator TIF2 contains three nuclear receptor‐binding motifs and mediates transactivation through CBP binding‐dependent and‐independent pathways
JJ Voegel, MJS Heine, M Tini, V Vivat, P Chambon, H Gronemeyer
The EMBO journal, 1998
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
A Nebbioso, N Clarke, E Voltz, E Germain, C Ambrosino, P Bontempo, ...
Nature medicine 11 (1), 77-84, 2005
International union of pharmacology. LXIII. Retinoid X receptors
P Germain, P Chambon, G Eichele, RM Evans, MA Lazar, M Leid, ...
Pharmacological reviews 58 (4), 760-772, 2006
The system can't perform the operation now. Try again later.
Articles 1–20